Boston, MA -- (SBWIRE) -- 09/12/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Real Goods Solar, Inc. (NASDAQ:RSOL), Zalicus Inc(NASDAQ:ZLCS), ChemoCentryx Inc (NASDAQ:CCXI), LDK Solar Co., Ltd (ADR) (NYSE:LDK)
Real Goods Solar, Inc. (NASDAQ:RSOL) stock gained 1.97% to $2.07. The company on August 12 has completed the acquisition of Syndicated Solar, Inc. The company paid net consideration of $2.5 million, plus 400,000 shares of Real Goods Solar unregistered Class A common stock, with the potential for the seller to earn up to $250,000 in additional earn-out payments following the close of the 2013 fiscal year and an additional 1.3 million shares of unregistered Class A common stock in performance based earn-outs over the next two and half year period.
How Should Investors Trade RSOL After The Recent Volatility? Get Free Report Here
Zalicus Inc(NASDAQ:ZLCS) shares decreased 4.36% to $0.765. The company on Sept. 9 announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013. The LEP clinical model is a type of experimental medicine study designed to provide both objective and subjective data on a drug's ability to modulate pain signaling.
How Should Investors Trade ZLCS After The Recent Volatility? Get Free Report Here
ChemoCentryx Inc (NASDAQ:CCXI) stock decreased 2.72% to $6.08. The company on Sept. 10 announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2, and the drug candidate is wholly owned by the Company. Examining data through the first 12 weeks of dosing in the ongoing 52 week trial, in which CCX140 is added on top of the standard of care for diabetic nephropathy patients (i.e., stable doses of angiotensin pathway inhibitors), the drug candidate appears well-tolerated in the patient population to date. The safety observations were consistent with a concurrent analysis by the Company's independent safety data monitoring committee, which independently assessed the interim data and recommended no changes to the ongoing study protocol.
Is CCXI A Good Buy After The Recent Price Movement? Find Out Here
LDK Solar Co., Ltd (ADR) (NYSE:LDK) shares closed at $1.58. The company on August 27 reported its unaudited financial results for the second quarter ended June 30, 2013. Net sales for the second quarter of fiscal 2013 were $114.7 million, compared to $104.3 million for the first quarter of fiscal 2013, and $235.4 million for the second quarter of fiscal 2012. Net loss for the second quarter of fiscal 2013 was $165.3 million, or a loss of $0.97 per diluted ADS, compared to net loss of $187.1 million, or a loss of $1.21 per diluted ADS for the first quarter of fiscal 2013 and net loss of $254.3 million, or a loss of $2.00 per dwiluted ADS for the second quarter of fiscal 2012.
Is LDK A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)